[Immunological markers of disease activity in the course of 2-CDA treatment of multiple sclerosis].
52 clinically definite multiple sclerosis (MS) patients were treated with subcutaneous injection of 5 mg 2-CDA in 5 consecutive days. The injection courses were repeated 6 times in one month interval. The MRI pattern and immunological markers were studied in serum and CSF before and after 6 months of treatment. The obtained results suggest that treatment with 2-CDA has not any significant effect on humoral immunological events in multiple sclerosis, what is in contrast to some normalization of cellular immunopathological processes.
Michałowska-Wender
G
G
Zespołu Neuroimmunologicznego Centrum Medycyny Doświadczalnej i Klinicznej PAN w Poznaniu.
Tokarz-Kupczyk
E
E
Losy
J
J
Sniatała-Kamasa
M
M
Wender
M
M
D015762:2-Chloroadenosine / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D000917:Antibody Formation; D000918:Antibody Specificity; D015703:Antigens, CD / Q000097:blood / Q000276:immunology; D000964:Antimetabolites, Antineoplastic / Q000276:immunology* / Q000627:therapeutic use*; D015415:Biomarkers; D003839:Deoxyadenosines / Q000276:immunology* / Q000627:therapeutic use*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007136:Immunoglobulins / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D010641:Phenotype; D015375:Receptors, Interleukin-2 / Q000097:blood / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid / Q000276:immunology
D015703:Antigens, CD; D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; D003839:Deoxyadenosines; D007136:Immunoglobulins; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D015762:2-Chloroadenosine; C055994:2-chloro-3'-deoxyadenosine